OtherBrief Communication
Preliminary clinical experience of cholecystokinin-2 receptor PET/CT imaging using the 68Ga-labeled minigastrin analog DOTA-MGS5 in patients with medullary thyroid cancer
Elisabeth von Guggenberg, Christian Uprimny, Maximilian Klingler, Boris Warwitz, Anna Sviridenko, Steffen Bayerschmidt, Gianpaolo Di Santo and Irene J. Virgolini
Journal of Nuclear Medicine January 2023, jnumed.122.264977; DOI: https://doi.org/10.2967/jnumed.122.264977
Elisabeth von Guggenberg
Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria, Austria
Christian Uprimny
Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria, Austria
Maximilian Klingler
Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria, Austria
Boris Warwitz
Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria, Austria
Anna Sviridenko
Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria, Austria
Steffen Bayerschmidt
Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria, Austria
Gianpaolo Di Santo
Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria, Austria
Irene J. Virgolini
Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria, Austria

Article Figures & Data
Additional Files
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 66, Issue 5
May 1, 2025
Preliminary clinical experience of cholecystokinin-2 receptor PET/CT imaging using the 68Ga-labeled minigastrin analog DOTA-MGS5 in patients with medullary thyroid cancer
Elisabeth von Guggenberg, Christian Uprimny, Maximilian Klingler, Boris Warwitz, Anna Sviridenko, Steffen Bayerschmidt, Gianpaolo Di Santo, Irene J. Virgolini
Journal of Nuclear Medicine Jan 2023, jnumed.122.264977; DOI: 10.2967/jnumed.122.264977
Preliminary clinical experience of cholecystokinin-2 receptor PET/CT imaging using the 68Ga-labeled minigastrin analog DOTA-MGS5 in patients with medullary thyroid cancer
Elisabeth von Guggenberg, Christian Uprimny, Maximilian Klingler, Boris Warwitz, Anna Sviridenko, Steffen Bayerschmidt, Gianpaolo Di Santo, Irene J. Virgolini
Journal of Nuclear Medicine Jan 2023, jnumed.122.264977; DOI: 10.2967/jnumed.122.264977
Jump to section
Related Articles
Cited By...
- Safety, Biodistribution, and Radiation Dosimetry of the 68Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Advanced Medullary Thyroid Cancer and Other Neuroendocrine Tumors
- Preclinical Evaluation of Minigastrin Analogs and Proof-of-Concept [68Ga]Ga-DOTA-CCK-66 PET/CT in 2 Patients with Medullary Thyroid Cancer